Clinical Trial Research
Phase III trial of CUV1647 begins in Polymorphic Light Eruption
Published in Clinical Trials Week, June 4th, 2007
Clinuvel Pharmaceuticals Limited (ASX:CUV, XETRA-DAX:UR9) is pleased to announce that the Phase III trial of CUV1647 in Polymorphic Light Eruption (PLE/PMLE) has begun in Europe. The first group of patients has received either the active implant containing photo-protective CUV1647 or a placebo implant. This Phase III multicentre, randomised, double blind, placebo controlled study follows the Phase II results from August 2006 in which CUV1647 significantly reduced the need for rescue medication, in the form of steroids or anti-inflammatory drugs, in PLE patients. The Phase III trial will further determine whether CUV1647 can prevent or reduce the severity of symptoms in patients with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2007-06-04)
More Articles from Clinical Trials Week
- Gastroenterology
Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW - Liver Cancer
The hepatitis C link: Diagnose, treat, transplant - Schizophrenia
Iloperidone Results Show Favorable Akathisia Profile - Actinic Keratosis
Fosfluridine Tidoxil shows effectiveness in Actinic Keratosis - Amyotrophic Lateral Sclerosis
Commencement of phase Ib clinical study for Myogane - Amyotrophic Lateral Sclerosis
CytRx Provides Operational Update - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
